Monitoring system for isolated limb perfusion based on a portable gamma camera

被引:3
作者
Orero, A. [1 ]
Vidal-Sicart, S. [1 ,2 ,3 ]
Roe, N. [1 ,4 ]
Muxi, A. [1 ]
Rubi, S. [1 ]
Duch, J. [1 ]
Rull, R. [5 ]
Pavon, N. [6 ]
Pons, F. [1 ,2 ,3 ]
Pavia, J. [1 ,2 ,4 ]
机构
[1] Hosp Clin Barcelona, Nucl Med Serv, Barcelona 08036, Spain
[2] IDIBAPS, Barcelona, Spain
[3] RTICC, Barcelona, Spain
[4] CIBER BBN, Barcelona, Spain
[5] Hosp Clin Barcelona, Serv Cirurgia, Barcelona 08036, Spain
[6] CSIC UV, Inst Fis Corpuscular, Valencia, Spain
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2009年 / 48卷 / 04期
关键词
Limb perfusion; tumour necrosis factor alfa; melphalan; radiotracer; gamma camera; leakage monitoring; TUMOR-NECROSIS-FACTOR; SOFT-TISSUE SARCOMAS; FACTOR-ALPHA; INTERFERON-GAMMA; RECURRENT MELANOMA; MULTICENTER TRIAL; TNF-ALPHA; MELPHALAN; TOXICITY; EFFICACY;
D O I
10.3413/nukmed-0223
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background: The treatment of malignant melanoma or sarcomas on a limb using extremity perfusion with tumour necrosis factor (TNF-alpha) and melphalan can result in a high degree of systemic toxicity if there is any leakage from the isolated blood territory of the limb into the systemic vascular territory. Leakage is currently controlled by using radiotracers and heavy external probes in a procedure that requires continuous manual calculations. The aim of this work was to develop a light, easily transportable system to monitor limb perfusion leakage by controlling systemic blood pool radioactivity with a portable gamma camera adapted for intraoperative use as an external probe, and to initiate its application in the treatment of MM patients. Methods: A special collimator was built for maximal sensitivity. Software for acquisition and data processing in real time was developed. After testing the adequacy of the system, it was used to monitor limb perfusion leakage in 16 patients with malignant melanoma to be treated with perfusion of TNF-alpha and melphalan. Results: The field of view of the detector system was 13.8 cm, which is appropriate for the monitoring, since the area to be controlled was the precordial zone. The sensitivity of the system was 257 cps/MBq. When the percentage of leakage reaches 10% the associated absolute error is +/- 1%. After a mean follow-up period of 12 months, no patients have shown any significant or lasting side-effects. Partial or complete remission of lesions was seen in 9 out of 16 patients (56%) after HILP with TNF-alpha and melphalan. Conclusion: The detector system together with specially developed software provides a suitable automatic continuous monitoring system of any leakage that may occur during limb perfusion. This technique has been successfully implemented in patients for whom perfusion with TNF-alpha and melphalan has been indicated.
引用
收藏
页码:166 / 172
页数:7
相关论文
共 31 条
  • [1] Radioguided surgery of non-palpable breast lesions
    Armas, F.
    Intra, M.
    Vega, V.
    Isla, C.
    Herandez, M. J.
    [J]. REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2007, 26 (02): : 107 - 120
  • [2] Efficacy of hyperthermic isolated limb perfusion for extremity-confined recurrent melanoma
    Brobeil, A
    Berman, C
    Cruse, CW
    De Conti, R
    Cantor, A
    Lyman, GH
    Joseph, E
    Rapaport, D
    Wells, K
    Reintgen, DS
    [J]. ANNALS OF SURGICAL ONCOLOGY, 1998, 5 (04) : 376 - 383
  • [3] Optimized procedure of real-time systemic leakage monitoring during isolated limb perfusion using a hand held gamma probe and 99mTc-HSA
    Casara, D
    Rubello, D
    Pilati, P
    Scalerta, R
    Foletto, M
    Rossi, CR
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2004, 25 (01) : 61 - 66
  • [4] CAVALIER.R, 1967, CANCER-AM CANCER SOC, V20, P1351, DOI 10.1002/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO
  • [5] 2-#
  • [6] Isolated limb perfusion with tumor necrosis factor and melphalan for non-resectable soft tissue sarcomas:: Long-term results on efficacy and limb salvage in a selected group of patients
    Cherix, Stephane
    Speiser, Melanie
    Matter, Maurice
    Raffoul, Wassim
    Lienard, Daniele
    Theumann, Nicolas
    Mouhsine, Elyazid
    Mirimanoff, Rene-Olivier
    Leyvraz, Serge
    Lejeune, Ferdy J.
    Leyvraz, Pierre-Francois
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2008, 98 (03) : 148 - 155
  • [7] Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group trial Z0020
    Cornett, Wendy R.
    McCall, Linda M.
    Petersen, Rebecca P.
    Ross, Merrick I.
    Briele, Henry A.
    Noyes, R. Dirk
    Sussman, Jeffrey J.
    Kraybill, William G.
    Kane, John M., III
    Alexander, H. Richard
    Lee, Jeffrey E.
    Mansfield, Paul F.
    Pingpank, James F.
    Winchester, David J.
    White, Richard L., Jr.
    Chadaram, Vijaya
    Herndon, James E., II
    Fraker, Douglas L.
    Tyler, Douglas S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) : 4196 - 4201
  • [8] CREECH R, 1956, JAMA-J AM MED ASSOC, V169, P339
  • [9] Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
    de Wilt, JHW
    ten Hagen, TLM
    de Boeck, G
    van Tiel, ST
    de Bruijn, EA
    Eggermont, AMM
    [J]. BRITISH JOURNAL OF CANCER, 2000, 82 (05) : 1000 - 1003
  • [10] Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas - The cumulative multicenter European experience
    Eggermont, AMM
    Koops, HS
    Klausner, JM
    Kroon, BBR
    Schlag, PM
    Lienard, D
    vanGeel, AN
    Hoekstra, HJ
    Meller, I
    Nieweg, OE
    Kettelhack, C
    BenAri, G
    Pector, JC
    Lejeune, FJ
    [J]. ANNALS OF SURGERY, 1996, 224 (06) : 756 - 765